Actively Recruiting
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Led by Navy General Hospital, Beijing · Updated on 2020-07-21
21
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study suggested that hydrogen has a potential as an effective and safe therapeutic agent on cGVHD.
CONDITIONS
Official Title
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent
- Male or non-pregnant female
- Patients younger than 65 years old
- Diagnosis of chronic graft-versus-host disease that is steroid-refractory or steroid-dependent
- Patient intolerant to steroid therapy
You will not qualify if you...
- Patients with stable disease not well controlled by current treatment
- Pregnancy
- HIV positive
- Severe liver or renal impairment (serum creatinine >2.5 mg/dl; serum bilirubin >2.5 mg/dl without hepatic cGVHD)
- Uncontrolled malignancies including persistence or relapse of hematopoietic malignancy
- Use of any other investigational agents within the last four weeks
- Cardiac insufficiency greater than grade II (New York Heart Association classification)
- Inability to comply with medical therapy or follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here